Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …

Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Background High-risk triple-negative breast cancers (TNBCs) are characterized by poor
prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy …

Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of
this disease. This Series article reviews the main achievements so far in the treatment of …

Purpose To determine the long-term prognosis in each phenotypic subset of breast cancer
related to residual cancer burden (RCB) after neoadjuvant chemotherapy alone, or with …

Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant
pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological …

Objective To determine the availability of data on overall survival and quality of life benefits
of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly …